levocetirizine
Trade name: xyzal
Small moleculeapproved
Approved
May 25, 2007
Levocetirizine is the active enantiomer of cetirizine. It is inverse agonist of H1 receptors. Levocetirizine hydrochloride was approved for treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria. — NCATS
Clinical trial activity
70 trials · 48 clinical orgs · 24 marketing orgs
Phase 1
13
Phase 2
27
Phase 3
20
Phase 4
25
Earliest trial started Dec 1, 2001 (NCT00520754)
Timeline
2000s
2010s
- Nov 26, 2010
Byondis — Marketing Organization
- Feb 24, 2011
Dr. Reddy's Laboratories — Marketing Organization
- Feb 24, 2011
Glenmark Pharmaceuticals — Marketing Organization
- Aug 22, 2011
Teva — Marketing Organization
- Nov 7, 2011
Padagis Us — Marketing Organization
- Jun 29, 2012
Hetero Labs Ltd — Marketing Organization
- Jan 31, 2013
Sun Pharmaceuticals — Marketing Organization
- Mar 26, 2013
Granules India — Marketing Organization
- Mar 26, 2013
Fosun — Marketing Organization
- Jul 26, 2013
Taro Pharmaceuticals — Marketing Organization
- Aug 21, 2014
Apotex — Marketing Organization
- Sep 9, 2014
Sciegen Pharmaceticals — Marketing Organization
- Jan 11, 2016
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Jan 11, 2016
Neogen — Marketing Organization
- Dec 20, 2016
Neopharma — Marketing Organization
- Dec 20, 2016
US Antibiotics — Marketing Organization
- May 15, 2017
Chartwell Pharmaceuticals — Marketing Organization
- May 15, 2017
Lannett Company, Inc. — Marketing Organization
- Nov 20, 2018
Micro Labs Ltd India — Marketing Organization
- Mar 28, 2019
Perrigo — Marketing Organization
2020s
- May 6, 2024
IPCA Laboratories Ltd. — Marketing Organization
Indications
Approved for
Studied for
- Allergy and Immunology · Phase 4
- Angioedema · Phase 3
- Anti-Allergic Agents · Phase 4
- Asthma · Phase 3
- Chronic Urticaria · Phase 4
- Colorectal Neoplasms · Phase 2
- Cough · Phase 2
- Dermatitis · Phase 3
- Dermatitis, Atopic · Phase 4
- Diabetic Nephropathies · Phase 2
- Eczema · Phase 3
- Fasting · Phase 1
- Healthy Volunteers · Phase 4
- Hypersensitivity · Phase 4
- Pruritus · Phase 4
- Rhinitis · Phase 4
- Rhinitis, Allergic · Phase 4
- Rhinitis, Allergic, Perennial · Phase 4
- Rhinitis, Allergic, Seasonal · Phase 4
- Rhinitis, Vasomotor · Phase 3
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Approval history
- approvedPriority reviewMay 25, 2007
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1- Mol. weight
- 388.9 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Over the Counter
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1201191 ↗
- WikipediaLevocetirizine ↗
- NCATS6U5EA9RT2O ↗
- ChEMBLCHEMBL1201190 ↗
Also known as
- 2-(2-{4-[(r)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
- 2-(2-{4-[(r)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
- (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
- (2-(4-((r)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid
- acetic acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
- acetic acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride
- cetirizine (r)-form dihydrochloride
- levocetirizine
- levocetirizine
- levocetirizine
- levocetirizine
- levocetirizine
- levocetirizine
- levocetirizine
- levocetirizine
- levocetirizine
- levocetirizine dihydrochloride
- levocetirizine dihydrochloride
- levocetirizine dihydrochloride
- levocetirizine dihydrochloride
- levocetirizine dihydrochloride
- levocetirizine hcl
- levocetirizine hydrochloride
- levocetirizine hydrochloride
- levocetirizine hydrochloride
- levocetirizine hydrochloride
- levocetirizine hydrochloride
- levocetirizine hydrochloride
- levocetrizine
- (r)-cetirizine
- ucb-28556
- ucb-28556
- ucb-28556
- xusal
- xyzal
- xyzal
- xyzal
- xyzal
- xyzal
- xyzal
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06816784 | Phase 2 | Feb 28, 2025 | Sheikh Zayed Medical College |
| NCT05638880 | Phase 2 | Dec 20, 2022 | Tanta University |
| NCT05565729 | Phase 1 | Oct 5, 2022 | Eli Lilly, Nektar Therapeutics |
| NCT04699604 | Phase 3 | Apr 28, 2021 | University of Kansas |
| NCT05348148 | N/A | Jun 16, 2020 | Camillians Saint Mary's Hospital Luodong |
| NCT04399525 | N/A | Oct 28, 2019 | Katholieke Universiteit Leuven |
| NCT03789422 | Phase 4 | Jul 31, 2019 | University of Grenoble |
| NCT04324918 | Phase 3 | Oct 23, 2018 | Hanmi Pharmaceutical, Yonsei University |
| NCT03545464 | Phase 3 | Jun 1, 2018 | Assistance Publique - Hôpitaux de Paris |
| NCT03555890 | Phase 1 | May 18, 2018 | GlaxoSmithKline, Zensei Pharmaceutical Co., Ltd. |
| NCT03371849 | Phase 1 | Jul 19, 2017 | Hanmi Pharmaceutical |
| NCT03673384 | N/A | Mar 2, 2015 | Nanhua University, Tzu Chi University |
| NCT02372604 | Phase 3 | Mar 1, 2015 | University of Lyon |
| NCT02551536 | Phase 4 | Apr 1, 2014 | Indira Gandhi Medical College |
| NCT01722162 | Phase 2 | Apr 1, 2013 | Washington University in St. Louis |
| NCT01651481 | Phase 1 | Jul 1, 2012 | Hanmi Pharmaceutical |
| NCT01640535 | Phase 3 | Jun 1, 2012 | Hanmi Pharmaceutical |
| NCT01622283 | Phase 1 | May 2, 2012 | GlaxoSmithKline |
| NCT01496911 | Phase 4 | Apr 1, 2012 | Royal Netherlands Navy, Utrecht University |
| NCT01563081 | Phase 3 | Apr 1, 2012 | GlaxoSmithKline |
Showing 20 of 70 trials
Page 1 / 4
Organizations
Research & Development (48)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 30 | 25 | 5 | 2001 |
| Hanmi Pharmaceutical | For profit | 6 | 6 | 2 | 2011 |
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2008 |
| Accutest Research Laboratories (I) Pvt. Ltd. | For profit | 2 | 0 | 1 | 2012 |
| Dr. Reddy's Laboratories | For profit | 2 | 2 | 1 | 2007 |
| Institut für Atemwegsforschung GmbH | Academic/Hospital | 2 | 2 | 1 | 2006 |
| IPCA Laboratories Ltd. | For profit | 2 | 2 | 1 | 2012 |
| Merck | For profit | 2 | 2 | 2 | 2003 |
| University of Kansas | Academic/Hospital | 2 | 2 | 2 | 2011 |
| Vimta Labs Ltd. | For profit | 2 | 0 | 1 | 2007 |
| AAADRS Clinical Research Center | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Association Asthma, Bulgaria | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Camillians Saint Mary's Hospital Luodong | Academic/Hospital | 1 | 1 | 1 | 2020 |
| CJ HealthCare Corp. | For profit | 1 | 1 | 1 | 2009 |
| Clinical Research International Limited | For profit | 1 | 1 | 1 | 2009 |
| CRI Ltd | For profit | 1 | 0 | 1 | 2009 |
| Derm Research, PLLC | For profit | 1 | 1 | 1 | 2009 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2022 |
| Faes Farma, S.A. | For profit | 1 | 1 | 1 | 2006 |
48 organizations
Page 1 / 3
Marketing (33)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Apotex | For profit | SYN | Aug 21, 2014 |
| Apotex | For profit | MKTG | Aug 21, 2014 |
| Byondis | For profit | MKTG | Nov 26, 2010 |
| Chartwell Pharmaceuticals | For profit | MKTG | May 15, 2017 |
| Dr. Reddy's Laboratories | For profit | SYN | Jan 19, 2018 |
| Dr. Reddy's Laboratories | For profit | MKTG | Feb 24, 2011 |
| Fosun | For profit | MKTG | Mar 26, 2013 |
| Glenmark Pharmaceuticals | For profit | MKTG | Feb 24, 2011 |
| Glenmark Pharmaceuticals | For profit | SYN | Feb 24, 2011 |
| Granules India | For profit | MKTG | Mar 26, 2013 |
| Hetero Labs Ltd | For profit | MKTG | Jun 29, 2012 |
| IPCA Laboratories Ltd. | For profit | MKTG | May 6, 2024 |
| Lannett Company, Inc. | For profit | MKTG | May 15, 2017 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | Jan 11, 2016 |
| Micro Labs Ltd India | For profit | MKTG | Nov 20, 2018 |
| Micro Labs Ltd India | For profit | SYN | Sep 17, 2013 |
| Neogen | For profit | MKTG | Jan 11, 2016 |
| Neopharma | For profit | MKTG | Dec 20, 2016 |
| Padagis Us | For profit | MKTG | Nov 7, 2011 |
| Perrigo | For profit | MKTG | Mar 28, 2019 |
| Perrigo | For profit | SYN | Nov 7, 2011 |
| Sanofi | For profit | SYN | May 25, 2007 |
| Sanofi | For profit | MKTG | May 25, 2007 |
| Sanofi-Aventis | For profit | NDA2 | May 25, 2007 |
| Sciegen Pharmaceticals | For profit | MKTG | Sep 9, 2014 |
| Sun Pharmaceuticals | For profit | SYN | Jan 31, 2013 |
| Sun Pharmaceuticals | For profit | SYN | Jun 26, 2015 |
| Sun Pharmaceuticals | For profit | MKTG | Jan 31, 2013 |
| Taro Pharmaceuticals | For profit | MKTG | Jul 26, 2013 |
| Taro Pharmaceuticals | For profit | SYN | Jul 26, 2013 |
| Teva | For profit | MKTG | Aug 22, 2011 |
| UCB | For profit | NDA | May 25, 2007 |
| US Antibiotics | For profit | MKTG | Dec 20, 2016 |